Q1 EPS Estimates for Globus Medical Decreased by Analyst

Globus Medical, Inc. (NYSE:GMED - Free Report) - Analysts at Zacks Research dropped their Q1 2025 earnings estimates for Globus Medical in a report released on Thursday, March 13th. Zacks Research analyst R. Department now anticipates that the medical device company will earn $0.73 per share for the quarter, down from their prior forecast of $0.79. The consensus estimate for Globus Medical's current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical's Q3 2025 earnings at $0.87 EPS, Q4 2025 earnings at $0.97 EPS, Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $0.99 EPS, Q4 2026 earnings at $1.14 EPS and FY2027 earnings at $4.49 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical device company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.10. The business had revenue of $657.29 million for the quarter, compared to the consensus estimate of $646.19 million. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%.

GMED has been the topic of several other reports. Morgan Stanley raised shares of Globus Medical from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. Barclays raised their price objective on shares of Globus Medical from $100.00 to $103.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. StockNews.com upgraded shares of Globus Medical from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Canaccord Genuity Group raised their price objective on shares of Globus Medical from $92.00 to $101.00 and gave the stock a "buy" rating in a research report on Friday, January 10th. Finally, Truist Financial cut their price objective on shares of Globus Medical from $90.00 to $82.00 and set a "hold" rating for the company in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $97.09.

Remove Ads

Globus Medical Stock Performance

Shares of NYSE:GMED traded up $0.25 during midday trading on Monday, hitting $73.59. The company's stock had a trading volume of 608,214 shares, compared to its average volume of 984,622. The business's 50 day simple moving average is $84.13 and its 200 day simple moving average is $79.75. The company has a market cap of $10.12 billion, a P/E ratio of 98.20, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19. Globus Medical has a 12-month low of $49.33 and a 12-month high of $94.93.

Insider Activity at Globus Medical

In related news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 18.54% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Globus Medical by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 10,863,834 shares of the medical device company's stock worth $898,548,000 after buying an additional 240,218 shares during the last quarter. State Street Corp grew its stake in shares of Globus Medical by 2.3% during the 3rd quarter. State Street Corp now owns 3,570,726 shares of the medical device company's stock worth $255,450,000 after purchasing an additional 81,371 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Globus Medical by 7.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,804,330 shares of the medical device company's stock worth $231,946,000 after purchasing an additional 199,556 shares during the period. Burgundy Asset Management Ltd. grew its stake in shares of Globus Medical by 1.7% during the 4th quarter. Burgundy Asset Management Ltd. now owns 2,618,108 shares of the medical device company's stock worth $216,544,000 after purchasing an additional 43,330 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Globus Medical by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,897,212 shares of the medical device company's stock worth $156,969,000 after purchasing an additional 12,151 shares during the period. Hedge funds and other institutional investors own 95.16% of the company's stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.